Deng Heping, Deng Hejun, Kim Chiho, Li Peng, Wang Xudong, Yu Yonghao, Qin Tian
Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
These authors contributed equally: Heping Deng, Hejun Deng.
Nat Synth. 2024 Mar;3(3):378-385. doi: 10.1038/s44160-023-00437-w. Epub 2023 Nov 27.
Nimbolide, a ring seco-C limonoid natural product, was recently found to inhibit the poly(ADP)-ribosylation (PARylation)-dependent ubiquitin E3 ligase RNF114. In doing so, it induces the 'supertrapping' of both PARylated PARP1 and PAR-dependent DNA-repair factors. PARP1 inhibitors have reshaped the treatment of cancer patients with germline / mutations partly through the PARP1 trapping mechanism. To this end, modular access to nimbolide analogues represents an opportunity to develop cancer therapeutics with enhanced PARP1 trapping capability. Here we report a convergent synthesis of nimbolide through a late-stage coupling strategy. Through a sulfonyl hydrazone-mediated etherification and a radical cyclization, this strategy uses a pharmacophore-containing building block and diversifiable hydrazone units to enable the modular synthesis of nimbolide and its analogues. The broad generality of our synthetic strategy allowed access to a variety of analogues with their preliminary cellular cytotoxicity and PARP1 trapping activity reported.
印楝素,一种环裂- C型柠檬苦素类天然产物,最近被发现可抑制聚(ADP)-核糖基化(PARylation)依赖性泛素E3连接酶RNF114。在此过程中,它会诱导PAR化的PARP1和PAR依赖性DNA修复因子的“超级捕获”。PARP1抑制剂部分通过PARP1捕获机制重塑了对患有种系/突变的癌症患者的治疗方法。为此,模块化获取印楝素类似物为开发具有增强PARP1捕获能力的癌症治疗药物提供了机会。在此,我们报告了通过后期偶联策略对印楝素进行的汇聚合成。通过磺酰腙介导的醚化反应和自由基环化反应,该策略使用含药效团的结构单元和可多样化的腙单元,实现了印楝素及其类似物的模块化合成。我们合成策略的广泛通用性使得能够获得多种类似物,并报道了它们初步的细胞毒性和PARP1捕获活性。